|
| |
Cytomegalo RetinitisDownload PDF containing detailed information.
Recent Publications on Cytomegalo Retinitis: |  |
Syphilitic retinitis with focal inflammatory accumulations.
A 42-year-old man with a history of human immunodeficiency virus and... | 27th October, 2006
| Department of Ophthalmology, New York University School of Medicine, New
| Ophthalmic Surg Lasers Imaging. 2006 Sep-Oct;37(5):429-31.
|
Press Releases About Cytomegalo Retinitis:
|
 |
| R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021 |
25th August, 2009 |
R-Tech Ueno, Ltd. |
TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R)
|
| Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors |
28th May, 2009 |
Neurotech Pharmaceuticals, Inc. |
LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical
|
| QLT announces completion of Phase Ia safety trial of its synthetic retinoid product |
12th March, 2009 |
QLT Inc. |
VANCOUVER, March 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced the results from a Phase Ia trial of QLT091001 in healthy
|
| Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island |
21st October, 2008 |
|
CUMBERLAND, Rhode Island, October 21 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company
focused on the development of sight-saving therapeutics for chronic retinal
|
| Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications - Retinitis Pigmentosa and Dry Age-Related Macular Degeneration |
3rd September, 2008 |
|
LINCOLN, Rhode Island, September 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company
focused on the development of sight-saving therapeutics for chronic retinal
|
BioPortfolio Ltd. offers e-mail and postal lists for Cytomegalo Retinitis scientists - we have details of around 0 individuals working on Cytomegalo Retinitis .
This page has been viewed 300 times
Recent Search Terms used to find this page: cytomegalo retinitis | cytomegalo retinitis | cytomegalo retinitis | cyto megalo retinitis | cytomegalo retinitis | cytomegalo retinitis | cytomegalo retinitis | cytomegalo-retinitis | cytomegalo-retinitis | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Cytomegalo Retinitis across BioPortfolio, or for Cytomegalo Retinitis Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
